Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Abbott Laboratories (ABT) stock in plain English

Free brief · no signupStart here
ABTPublished Nov 15, 2026
Abbott Laboratories
Healthcare · Medical Devices
Sells continuous glucose monitors, cardiovascular devices, diagnostic lab tests, infant formula, and branded generic medications.
Assets:
FreeStyle Libre lineContinuous glucose monitors used by over five million patients globally
Worldwide manufacturingOperates dozens of plants across nutrition, diagnostics, and medical devices
Infant nutrition plantsMajor production sites including the flagship facility in Sturgis, Michigan
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

54
OPS ScoreOperating finances
Latest quote
-0.58%$103.87
$179.90B
38.4×
$48.23B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ABT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Abbott Laboratories (ABT) do?

Abbott Laboratories (ABT) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells continuous glucose monitors, cardiovascular devices, diagnostic lab tests, infant formula, and branded generic medications. It is worth $179.90B on the market and sold $48.23B over the last year.

Market cap
$179.90B
P/E ratio
38.4×
Annual sales
$48.23B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 15, 2026

Brands and businesses behind ABT

  • FreeStyle Libre: Sells continuous glucose monitoring sensors and readers directly to patients and pharmacies.
  • Ensure: Sells adult nutritional shakes and meal replacements through retail grocers, pharmacies, and healthcare systems.
  • Similac: Sells infant formula powders and ready-to-feed liquids through retail channels and hospital contracts.
  • Pedialyte: Sells electrolyte hydration drinks and freezer pops to retail consumers and medical institutions.
  • Glucerna: Sells specialized nutrition shakes and snack bars formulated for people managing diabetes.
  • PediaSure: Sells nutritional growth drinks and powders targeted at children through retail stores.

ABT’s flags, in plain English

Each flag is a number from Abbott Laboratories’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Wide Gross Margin

Gross margin of 52.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Pays You to Hold

Pays a 2.51% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Priced for Perfection

Priced at 38.4 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

Questions about ABT

How big is Abbott Laboratories?

Abbott Laboratories’ market cap is $179.90B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $48.23B: what customers paid the company over the last year, before any costs.

What is ABT’s P/E ratio?

ABT’s P/E ratio is 38.4×. Investors pay about 38.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ABT?

Product recalls and past contamination issues in infant nutrition facilities expose the company to ongoing civil lawsuits and federal regulatory scrutiny. That is one risk on Abbott Laboratories’ card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Abbott Laboratories’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ABT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card